The global inhalation anesthesia market size is projected to reach USD 1.42 billion by 2025, at a lucrative CAGR of 3.5% over the forecast period, according to a new report by Grand View Research, Inc. Key factors contributing to its rapid growth include increasing prevalence of cancer, cardiovascular, respiratory, neurological, gastrointestinal, orthopedic, and spinal diseases and disorders.
Furthermore,
increasing number of emergency cases and demand for short stay ambulatory day
care surgical procedure are amongst critical success factors attributed to the
market growth. Access to universal health insurance coverage for a wider
population base coupled with constant improvements in healthcare infrastructure
in various developing countries are expected to positively impact the number of
surgeries performed, thus increasing the usage of inhalation anesthetics.
On
the basis of product, the inhalation anesthesia market is classified into
sevoflurane, isoflurane, and desflurane. These products are used for induction
and maintenance of anesthesia for patients during surgical procedures.
Sevoflurane led the product segment in 2018 and is anticipated to grow at a
lucrative rate over the forecast period, attributed to its therapeutic
advantages, low cost, and higher potency for the induction of anesthesia. On
the other hand, isoflurane is expected to witness the fastest CAGR of 6.3% over
the forecast period, due to its increasing use in maintenance of anesthesia for
treatment of weak or geriatric patients owing to its sparing effect on
cardiovascular function.
On
the basis of regions, the market is broadly classified into North America,
Europe, Asia Pacific, Latin America, and Middle East and Africa (MEA). North
America held the leading market share of USD 456.0 million and is anticipated
to witness lucrative CAGR over the forecast period. This is owing to increasing
prevalence of chronic diseases coupled with the presence of advanced healthcare
facilities. On the other hand, Asia Pacific was anticipated to witness the
fastest CAGR of 4.0% due to increasing population and number of patients
suffering from chronic population.
Some
of the key players operating in this market include Halocarbon Products
Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co.
Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius
Kabi AG, and AbbVie Inc.
Full Research Report On Inhalation Anesthesia Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/inhalation-anesthesia-market
Further key
findings from the report suggest:
- Sevoflurane
product segment led the market in terms of revenue, valued at USD 768.6
million, in 2018
- Isoflurane
product segment is anticipated to expand at the fastest CAGR of 6.3% owing
to its increasing use in the treatment of weak and geriatric patients
owing to its low effect on cardiovascular function
- North America
led the market in 2018 with a revenue of USD 456.0 million owing to the
presence of advanced healthcare facilities, strong reimbursement scenario,
and prevalence of chronic diseases
- Key players
operating in the inhalation anesthesia market include Halocarbon Products
Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical
Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co.
Ltd.; Fresenius Kabi AG, and AbbVie Inc.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/inhalation-anesthesia-market/request/rs1
Grand View Research has
segmented the global inhalation anesthesia market on the basis of product and
region:
Inhalation
Anesthesia Product Type Outlook (Revenue, USD Million, 2014 - 2025)
- Sevoflurane
- Isoflurane
- Desflurane
Inhalation
Anesthesia Application Type Outlook (Revenue, USD Million, 2014 - 2025)
- Induction
- Maintenance
Inhalation
Anesthesia Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment